F. Hoffmann-La Roche AG


About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

Roche retains sole responsibility for content © 2020 F. Hoffmann-La Roche AG. All trademarks used or mentioned in this release are protected by law.

1 December 2018 - 30 November 2019

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 December 2018 - 30 November 2019 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

Count Share
139 48.63

Outputs by subject (Share)

Subject Count Share
Chemistry 23 12.08
7 4.72
2 1.40
2 0.36
1 0.40
1 0.10
1 0.02
6 4.78
2 0.29
1 0
Life Sciences 119 36.65
Physical Sciences 5 0.93

Highlight of the month

Drug engineered to activate tumour-specific T cells



A new drug candidate that enhances anti-tumour immune responses could offer a safe and effective way to bolster the cancer-killing potential of other immunotherapeutics.

A Roche-led team engineered an antibody-like drug to activate immune cells by binding a co-stimulatory molecule called 4-1BB found on the surface of T cells.

Unlike previous drugs designed to do the same thing — therapies that ultimately failed in clinical trials owing to liver toxicity problems — the new Roche agent does not damage the liver since it contains mutations in the region that binds to liver cells.

The drug also contains a domain that binds a protein found in the supporting tissues that surround many cancers, thereby allowing for selective targeting of tumours.

In mouse models and human tissue samples, the drug improved the functionality of tumour-infiltrating T cells. And combination treatment with other immunotherapy agents eradicated aggressive tumours in mice.

A variant of this novel drug is now in early-stage human testing.

Supported content

  1. Science Translational Medicine 11, eaav5989 (2019). doi: 10.1126/scitranslmed.aav5989

View the article on the Nature Index

See more research highlights from F. Hoffmann-La Roche AG

More research highlights from F. Hoffmann-La Roche AG

1 December 2018 - 30 November 2019

International vs. domestic collaboration by Share

  • 7.09% Domestic
  • 92.91% International

Note: Hover over the graph to view the percentage of collaboration.

Note: Collaboration is determined by the fractional count (Share), which is listed in parentheses.

Affiliated joint institutions and consortia

Return to institution outputs